

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Henderson et al.

Confirmation No: 7222

Serial No.: 10/588,630

Group Art Unit: 1651

Filed: August 4, 2006

Examiner: Tiffany Maureen Gough

For: Liquefaction Processes

INFORMATION DISCLOSURE STATEMENT (IDS) UNDER 37 CFR 1.97(d)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with 37 C.F.R. 1.56, 1.97 and 1.98, Applicants submit herewith references which may be material to the patentability of this application and with respect to which there may be a duty to disclose. While the references may be material under 37 C.F.R. 1.56, it is not intended to constitute an admission that the references are prior art. The filing of this IDS shall not be construed as a representation that no other material references than those listed exist or that a search has been conducted.

The references are listed in Form PTO/SB/08A, which is in accordance with the requirements of M.P.E.P. 609. Copies of the foreign patent and non-patent literature documents are enclosed. Copies of the U.S. patent documents are not provided in accordance with the waiver of that requirement under 37 C.F.R. 1.98.

It is respectfully requested that these references be considered by the USPTO in its examination of the above-identified application and be made of record therein.

This IDS is being filed after the mailing date of any of a final action under § 1.113, a notice of allowance under § 1.311, or an action that otherwise closes prosecution, but before, or simultaneously with, the payment of the issue fee. In accordance with 37 C.F.R. § 1.97(d), Applicants enclose the statement specified in 37 C.F.R. § 1.97(e) and the fee set forth in 37 C.F.R. § 1.17(p).

All required fees were charged to Novozymes North America, Inc.'s Deposit Account No. 50-1701 at the time of electronic filing. The USPTO is authorized to charge this Deposit Account should any additional fees be due.

Respectfully submitted,

Date: August 18, 2011

/Elias Lambiris, Reg. # 33728/
Elias J. Lambiris, Reg. No. 33,728
Novozymes North America, Inc.
500 Fifth Avenue, Suite 1600
New York, NY 10110
(919) 494-3405